What is Neuraceq, and what is it used for?
Neuraceq is the brand name for florbetaben F 18, a radioactive imaging medicine used in PET scans to help detect amyloid plaques in the brain. It is used for evaluating adults with cognitive impairment to support assessment of Alzheimer’s disease pathology. [1]
How does Neuraceq PET imaging work?
Neuraceq contains florbetaben labeled with the radioactive isotope F 18. After injection, it circulates and binds to beta-amyloid plaques. A PET scan then captures the distribution of the tracer to classify amyloid status. [1]
What do the results mean (amyloid-positive vs amyloid-negative)?
Clinicians interpret Neuraceq PET results as indicating whether amyloid plaques are present at a level consistent with amyloid pathology. An amyloid-positive scan supports Alzheimer’s disease pathology as a contributor to cognitive impairment, while an amyloid-negative scan suggests amyloid plaques are not present at a level consistent with amyloid pathology. [1]
Who is Neuraceq for, and who should not use it?
Neuraceq is intended for adult use in the context of diagnostic evaluation of cognitive impairment when amyloid PET information is appropriate. It should be used only under the direction of qualified clinicians and in facilities equipped to handle radioactive drugs. Specific contraindications and patient eligibility details are provided in the prescribing information. [1]
How is Neuraceq administered, and what should patients expect?
Neuraceq is administered as an intravenous injection before PET imaging. Patients are imaged after the tracer is given, and the exact timing and scan protocol follow the radiopharmacy and PET center procedures described in the product information. [1]
What are the main risks and side effects?
As with other PET tracers, Neuraceq exposes patients to ionizing radiation from the injected F 18. The prescribing information also describes potential adverse reactions related to the injection and imaging process; these are generally uncommon, but patients should review the listed risks with their clinician. [1]
Neuraceq vs other amyloid PET tracers (what’s the difference)?
Neuraceq is one of several amyloid PET imaging options. Other tracers use different compounds and radiolabels but aim to assess amyloid plaque burden similarly. The choice between tracers depends on availability, clinical workflow, and how the imaging is interpreted in the local setting. [1]
How long has Neuraceq been around, and is it still available?
Neuraceq is an established amyloid PET tracer, but availability can vary by country and imaging center. Coverage and access depend on local regulatory approvals and reimbursement policies. [1]
Sources
- FDA Prescribing Information (Neuraceq / florbetaben F 18). https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207634